Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.
Deciphering which businesses can sustain their high growth rates is a challenge for even the most seasoned professionals, which is why we started StockStory. Keeping that in mind, here are three growth stocks with significant upside potential.
AppLovin (APP)
One-Year Revenue Growth: +21.1%
Sitting at the crossroads of the mobile advertising ecosystem with over 200 free-to-play games in its portfolio, AppLovin (NASDAQ: APP) provides software solutions that help mobile app developers market, monetize, and grow their apps through AI-powered advertising and analytics tools.
Why Are We Backing APP?
- Market share has increased as its 30.9% annual revenue growth over the last two years was exceptional
- User-friendly software enables clients to ramp up spending quickly, leading to the speedy recovery of customer acquisition costs
- Impressive free cash flow profitability enables the company to fund new investments or reward investors with share buybacks/dividends
AppLovin’s stock price of $659 implies a valuation ratio of 32.1x forward price-to-sales. Is now the right time to buy? Find out in our full research report, it’s free for active Edge members.
Doximity (DOCS)
One-Year Revenue Growth: +20.2%
With over 80% of U.S. physicians as members of its digital community, Doximity (NYSE: DOCS) operates a digital platform that enables physicians and other healthcare professionals to collaborate, stay current with medical news, manage their careers, and conduct virtual patient visits.
Why Is DOCS a Top Pick?
- Winning new contracts that can potentially increase in value as its billings growth has averaged 20.1% over the last year
- Fast payback periods on sales and marketing expenses allow the company to invest heavily and onboard many customers concurrently
- Strong free cash flow margin of 50.2% enables it to reinvest or return capital consistently
At $44.04 per share, Doximity trades at 13x forward price-to-sales. Is now a good time to buy? See for yourself in our full research report, it’s free for active Edge members.
Bowhead Specialty (BOW)
One-Year Revenue Growth: +33.4%
Named after the Arctic bowhead whale known for navigating challenging waters, Bowhead Specialty Holdings (NYSE: BOW) is a specialty insurance company that provides customized coverage for complex and high-risk commercial sectors.
Why Will BOW Beat the Market?
- Strong 37.9% annualized net premiums earned expansion over the last two years shows it’s capturing market share this cycle
- Expected revenue growth of 20.7% for the next year suggests its market share will rise
- Balance sheet strength has increased this cycle as its 74.5% annual book value per share growth over the last two years was exceptional
Bowhead Specialty is trading at $28.09 per share, or 2.1x forward P/B. Is now the right time to buy? Find out in our full research report, it’s free for active Edge members.
High-Quality Stocks for All Market Conditions
Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.
The names generating the next wave of massive growth are right here in our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today.
